This page shows the latest Licensing deals news and features for those working in and with pharma, biotech and healthcare.
Takeover is latest in a string of billion-plus deals signed by Gilead. ... The takeover is the latest in a string of big billion dollar-plus licensing and acquisition deals signed by Gilead since the start of 2019 under new chief executive Daniel
There has been a flurry of licensing deals in the coeliac disease area in recent months, including deals between GlaxoSmithKline and Sitari and Roche/Genentech and Parvus, as drugmakers eye a
It’s the first licensing deal for the company and is also thought to be the largest ever agreed by a Singapore biotech, with Boehringer agreeing to pay up to 1bn ( ... a series of licensing deals as well as its in-house research.
generic products, over a ten-year period, and has agreed licensing deals for three early-stage cancer drugs with Chinese biotech firms.
Has potential in cardiovascular and metabolic diseases. Pfizer has bolted on an antisense drug with potential in cardiovascular and metabolic diseases to its pipeline via a licensing deal with Ionis’ Akcea ... affiliate. The big pharma – which has
Lundbeck hasn’t traditionally been a particularly active player in M&A, preferring to rely mainly on its in-house R&D and smaller-scale licensing deals, but has stepped up ... the pace of deals under new CEO Deborah Dunsire (pictured below).
More from news
Approximately 2 fully matching, plus 86 partially matching documents found.
the pipeline, the use of technology in medicine is expected to grow and so are the associated deals, mergers and acquisitions. ... They also can help identify collaboration opportunities including partnerships, licensing deals and merger or acquisition
returns. That includes an exit from areas like neurology – which predates Bourla’s appointment as CEO but was set up while he was COO – and a series of bolt-on deals ... Meanwhile, Galapagos looks set to continue adding to its pipeline through
Furthermore, increases. in region or market-specific licensing deals for launch products have led companies to devolve to region-specific cross-functional teams for tailored launch preparation, allowing different thinking to
Mega-mergers are also becoming less frequent; instead, we’re seeing fewer but larger deals. ... Based on CMR International data, since 2015 we have seen the number of drug commercialisation/licensing deals continue to gradually decline while the
Licensing &. research. collaboration. $550m. Novartis/. Mylan. TOBI Podhaler and TOBI solution for cystic fibrosis. ... Licensing &. collaboration. $40m. All deals are for worldwide rights unless stated otherwise:.
More from intelligence
Approximately 0 fully matching, plus 33 partially matching documents found.
Edwin Moses, CEO of Ablynx, said: “Markus brings extensive experience in leading business development teams and executing licensing deals and acquisitions.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...